

# Evenlode Income

MONTHLY EDITION, November 2013

All data as at 1 November 2013

IMA sector	UK Equity Income
Launch date	19 Oct 2009
Fund value	£41.3 million
Holdings	29
Historic yield	3.4%
Div ex dates	1 Mar, Jun, Sep, Dec
Div pay dates	end Apr, Jul, Oct, Jan


## PRICES

A Income	149.07p
A Accumulation	152.09p
B Income	176.15p
B Accumulation	172.70p

## TOP 10 HOLDINGS

1	Glaxosmithkline	8.1%
2	Unilever	7.8%
3	Reckitt Benckiser	6.8%
4	Reed Elsevier	5.7%
5	Sage	5.0%
6	Pearson	5.0%
7	Astrazeneca	4.8%
8	Smith & Nephew	4.8%
9	Jardine Lloyd Thomson	4.4%
10	Procter & Gamble	4.4%
	<b>Top 10 Total</b>	<b>57.0%</b>

## SIZE ALLOCATION



## SECTOR ALLOCATION

Consumer Goods	33.9%
Healthcare	22.1%
Media	11.6%
Technology	10.4%
Financials	7.6%
Engineering	5.0%
Support Services	4.2%
Cash & Income	2.6%
Retail	2.5%

## FURTHER INFORMATION

Please contact Spring Capital Partners, in the first instance.

Tel 020 3195 0076  
 Email [evenlode@springcapitalpartners.com](mailto:evenlode@springcapitalpartners.com)  
 Visit [springcapitalpartners.com](http://springcapitalpartners.com)



Global markets rebounded strongly in October following a compromise on the US debt ceiling and the subsequent end to the US government shutdown.

The third quarter earnings season has now come and gone and results in general have been solid, though not as buoyant as one might expect given the sharp rise in stock prices this year. The trend of moderating conditions in developing markets offset by less terrible conditions in developed markets continues to be a general theme, but the pattern is a very patchy one. Margin expansion was also a feature for several companies with stocks such as Glaxosmithkline and AB Inbev reporting sharply higher earnings (up more than 10%) on pedestrian sales figures thanks to tight management of expenditure.

The fund rose +5.0% compared to +4.3% for the UK market and +4.6% for the IMA UK Equity Income sector. The biggest positive contributors were Unilever, Glaxosmithkline, Reckitt Benckiser and Procter & Gamble. Unilever and Glaxo rallied after recent weakness thanks to reassuring earnings announcements, as did P & G. Reckitt announced strong third quarter sales growth and a strategic review for its pharmaceutical business. This will likely result in its disposal and leave a tightly focused company with more than 70% exposure to the very attractive health and hygiene categories. There were no negative contributors to return over the month.

Hugh Yarrow, Investment Director

## PERFORMANCE SINCE LAUNCH



■ A - Wise Investments - Evenlode Income B Inc TR in GB [76.56%]  
 ■ B - IMA UK Equity Income TR in GB [59.17%]

19/10/2009 - 01/11/2013 Data from FE 2013

Past performance is not a reliable indicator of future performance

## CUMULATIVE PERFORMANCE<sup>+</sup>

	YTD	3 month	6 month	1 year	3 year	Since launch*
Evenlode Income B Inc	+23.4%	+1.9%	+6.9%	+25.4%	+52.6%	+76.6%
IMA UK Equity Income	+21.3%	+3.8%	+9.8%	+25.6%	+41.7%	+59.2%
Rank In Sector (B Inc)	31/96	79/98	73/98	45/95	11/86	8/84
Quartile (B Inc)	2	4	3	2	1	1

## DISCRETE ANNUAL PERFORMANCE<sup>+</sup>

	YTD	2012	2011	2010	2009*	2008
Evenlode Income B Inc	+23.4%	+12.8%	+2.7%	+19.7%	+3.2%	n/a
IMA UK Equity Income	+21.3%	+14.4%	-2.9%	+15.3%	+2.5%	n/a

\*From launch date: 19 October 2009



Hugh Yarrow is lead portfolio manager of Evenlode Income. He joined Wise in 2009 and launched Evenlode Income in October 2009. From 2002 to 2009 Hugh managed several equity income funds at Rathbone Unit Trust Management, having graduated from the University of Edinburgh with a first-class degree in philosophy and mathematics. He is a fellow of the Chartered Institute for Securities and Investment and holds the Investment Management Certificate.



Ben Peters is co-manager of Evenlode Income. Ben joined Wise in 2008 and has been the investment analyst for Evenlode Income since the fund's launch. He became co-manager in December 2012. Ben is a member of the CFA Society of the UK and holds the Investment Management Certificate. He also holds a doctorate from the University of Oxford and a first-class degree from University College London, both in the field of physics.

<sup>+</sup>All performance data used on this factsheet is total return, bid-to-bid, net of UK withholding tax, and sourced from Financial Express. The fund's main unit was changed to B shares on 1 December 2012 to comply with RDR regulation.

## B SHARES

SEDOL Codes

B Acc Shares B40SMR2

B Inc Shares B40Y5R1

Minimum Lump Sum

£1,000

Initial Charge

0%

Investment Management Fee

0.75% taken from capital

Ongoing Charges Figure\*

(includes Investment Management Fee)

1.25% taken from capital

Regular Savings Option Available?

Yes - minimum £50 per month

## A SHARES (LEGACY CLASS)

SEDOL Codes

A Acc Shares B42KPP5

A Inc Shares B42KJH5

Minimum Lump Sum

£1,000

IFA Legacy Trail Commission

0.5% p.a.

Investment Management Fee

0.75% p.a.

Ongoing Charges Figure\*

(includes IFA legacy trail commission and investment management fee)

1.75% p.a. taken from capital

Regular Savings Option Available?

Yes - minimum £50 per month

\*The Ongoing Charges Figure is based on the expenses incurred by the fund for the 12 months ended 28th February 2013. The figure may vary year to year.

## EVENLODE INCOME: FUND ATTRIBUTES

- Aim to provide attractive long-term total returns with an emphasis on income
- Disciplined value-orientated investment process
- Focused portfolio of c.30 shares offering a combination of high and growing cash flows and low fundamental business risk
- Low portfolio turnover
- Minimum of 80% in UK shares and up to 20% in overseas shares and / or cash
- No constraints by sector or company size

## HOW TO INVEST

Evenlode Income is available as an OEIC and is also suitable to include in stocks and shares ISAs. You can buy shares in the fund by visiting [www.tbailey.co.uk/wise](http://www.tbailey.co.uk/wise); by telephoning the TB Wise Investor Dealing Line on 0115 988 8258 (open business days between 9am and 5pm); or through various third parties including Cofunds, Transact, Ascentric, Hargreaves Lansdown, Axa Winterthur, Axa Elevate and Standard Life.

## CONTACT US

The Long Barn  
Chalford Park Barns  
Oxford  
Chipping Norton  
Oxon  
OX7 5QR

0845 803 3433

[www.wiseinvestment.co.uk](http://www.wiseinvestment.co.uk)

Authorised Corporate  
Director & Administrator  
T. Bailey Fund Managers Ltd  
(see [www.tbailey.co.uk/wise](http://www.tbailey.co.uk/wise))

Wise  Funds

## RISK WARNINGS

Full details of the TB Wise Funds, including risk warnings, are published in the TB Wise Funds Prospectus, the TB Wise Supplementary Information Document (SID) and the TB Wise Key Investor Information Documents (KIIDs) which are available on request and at [www.wiseinvestment.co.uk](http://www.wiseinvestment.co.uk). The TB Wise Funds are subject to normal stock market fluctuations and other risks inherent in such investments. The value of your investment and the income derived from it can go down as well as up, and you may not get back the money you invested. Capital appreciation in the early years will be adversely affected by the impact of initial charges and you should therefore regard your investment as medium-to-long term. As a concentrated portfolio of 20 to 30 investments Evenlode Income carries more risk than a fund spread over a large number of stocks. The fund has the ability to invest in derivatives for the purposes of EPM, which may restrict gains in a rising market. Investments in overseas equities may be affected by changes in exchange rates, which could cause the value of your investment to increase or diminish. Every effort is taken to ensure the accuracy of the data used in this document but no warranties are given. Wise Investments Limited is authorised and regulated by the Financial Conduct Authority, No. 230553. T. Bailey Fund Managers Limited is authorised and regulated by the Financial Conduct Authority, No. 190293

Wise Funds is a trading brand of Wise Investments Limited.